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Recommendations for Determining Equivalence of 
Inhaled Medications 
(1) Evaluation of therapeutic equivalence is the pre- 
ferred assessment in comparisons of the performance 
of different medication and inhalation device combi- 
nations, although there will be circumstances where 
this may not be practicable. 
(2) Pharmacodynamic assessments are important in 
the evaluation of equivalence of different inhaled 
medications via metered-dose inhalers (MDIs), with 
or without spacer devices, dry powder inhalers 
(DPIs), and nebulizers. However, it should be noted 
that the power of pharmacodynamic assessments is 
comparatively low, which necessitates the use of 
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large numbers of patients with consequent ethical 
considerations, particularly in long-term studies. 
(i) For ‘bronchodilator’ medications (B-agonists, 
anti-cholinergics), dose-response profiles should be 
determined in asthmatic patients, representing three 
grades of severity (mild, moderate and severe), in a 
range of ages from 8 years upwards, and including 
sufficient numbers of children, adults and the elderly. 
The study could be a straightforward assessment of 
bronchodilator activity, but should preferably 
comprise a bronchoprovocation study (to inhaled 
methacholine or histamine). It is important to 
standardize the bronchoprovocation tests. Safety 
assessments should include heart rate, electrocardio- 
gram, finger tremor, and serum glucose and potas- 
sium. Additional adverse events should be recorded 
and compared. The study could be merely an acute 
assessment, but optimally it should be repeated after 
steady-state dosing. 
(ii) For glucocorticosteroids, a long-term study (at 
least 1 month duration) is necessary, with subjects 
encompassing a range of ages and disease severity. 
Efficacy assessments include improvements in morn- 
ing and evening peak flow, reduction in response to 
bronchoprovocation, reduction in use of relief bron- 
chodilator medication, and lower incidence of acute 
exacerbations. Safety assessments should include 
tests of the integrity of the hypothalamopituitary- 
adrenal axis and incidence of local side effects, for 
example oropharyngeal candidiasis (confirmed by 
swabs and microscopy) and dysphonia. 
(iii) For non-steroidal ‘anti-allergies’ (cromogly- 
cate, nedocromil), there is currently no ideal protocol 
for demonstrating therapeutic equivalence. The best 
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available evaluation would be a comparison of pro- 
tection in bronchoprovocation tests using ‘indirect’ 
challenges, for example standardized exercise or 
inhalation of adenosine monophosphate. 
In each of the three assessments above (i-iii), an 
inhaler technique which is optimal for all the study 
subjects (i.e. to include the least ‘capable’ subject) 
should be adopted as the standard throughout. 
Patients with upper or lower respiratory tract infec- 
tions, and current smokers, should be excluded from 
the study. 
(3) In vitro distribution studies, provided they are 
rigorously executed using appropriate equipment (see 
below), can allow careful scrutiny of potential differ- 
ences between inhaled products, with greater power 
than can be achieved by pharmacodynamic testing. 
These tests should be designed to determine (i) 
equivalence of shot potency and (ii) equivalence of 
aerosol characteristics. For MDIs, the effect of pre- 
liminary actuations (‘priming’) should be assessed, 
and the results from primed and unprimed devices 
compared. The MD1 should be considered unreliable 
if a significant (2 20%) difference is found between 
the two. For DPIs, the performance of different 
devices should be compared at constant pressure 
drops, for example at 100 and 200 mmH,O, rather 
than constant flow rates. 
Unless limited by the sensitivity of available assays, 
MDIs should be evaluated for equivalence using the 
dose regimen routinely employed, commonly one or 
two actuations, rather than the 10 actuations recom- 
mended in the British Pharmacopoeia. The device 
should deliver 80-120% of the labelled dose. Similar 
considerations apply to DPIs. 
Rather than defining an arbitrary ‘respirable 
fraction’, the percentage of particles in each size 
range should be determined and compared. The more 
stages employed in the sampling device, the more 
detailed this characterization will be, and the greater 
the power to demonstrate potential difference 
between different products. Consequently, a multi- 
stage impactor, for example the eight-stage Andersen 
sampler, rather than the twin impinger, is the test 
apparatus of choice. The sampler should have a 
standardized inlet geometry and the methodology 
employed should be rigidly standardized. 
(4) In vivo radiolabel deposition studies give a more 
accurate estimate of drug deposition than in vitro 
studies, and essentially provide an assessment of bio- 
equivalence between different inhaled medications. 
They give information on drug deposition not only 
in the lung, but also in other areas of the body 
(oropharynx and gastrointestinal tract), and can be 
used in assessment of patient inhaler technique. If an 
inhalation device is of an entirely novel design, in vivo 
deposition studies should constitute part of the 
development programme. Many manufacturers rou- 
tinely perform these studies for marketing purposes. 
Wherever practicable, these studies should be carried 
out using a directly-labelled drug formulation rather 
than a labelled marker (e.g. Teflon particles). Depo- 
sition patterns within the lungs may be very different 
in patients compared with healthy volunteers. 
(5) Pharmacokinetic studies are generally of limited 
value and are not essential in assessment of equiva- 
lence. The low plasma concentrations of drug 
attained after inhalation limits the practicability and 
reliability of pharmacokinetic analysis. However, the 
recent development of differential urinary excretion 
analysis is of interest and merits further evaluation. 
Face masks are a common aid to inhalation of drugs 
by children. Pharmacokinetic evaluation of drug- 
face mask combinations may be confounded by avid 
absorption of drug from nasal passages. 
(6) Spacer devices add complexity to the assessment 
of equivalence of inhaled medications. Comparison 
of different inhaler and spacer combinations should 
be carried out using similar study designs to those 
detailed above, in particular pharmacodynamic 
studies and use of a multi-stage sampler for in vitro 
deposition analysis. In vivo deposition studies would 
give valuable information on the effect of the spacer 
on drug delivery. Pharmacokinetic studies would be 
optional. 
Drug adherence to the inner surface of the spacer 
should be controlled. Washing the device in warm 
soapy water followed by rinsing and air-drying prior 
to dosing, both for in vitro and in vivo studies, reduces 
static charge, and therefore drug adherence to the 
internal surface of the device, and facilitates 
standardization between spacers. There should be 
only a single actuation of the MD1 into the spacer 
before each inhalation, and inhalation should be 
immediately after actuation to ensure that the 
maximal dose is obtained. 
(7) The huge variety of nebulizers and nebuhzed 
drug dosage available, whether for routine domicili- 
ary use or to alleviate acute attacks of asthma, is a 
cause for concern. Many manufacturers of nebulizer 
solutions or suspensions do not routinely recommend 
a specific nebulizer or nebulizers for use with their 
medication, and in practice a wide variety might 
be used, leading to great variability in the dose 
delivered. Manufacturers should be required to rec- 
ommend one or more specific nebulizer(s) for use 
with their drug (preferably at least one jet and 
one ultrasonic apparatus) and should submit both 
in vitro and clinical data in support of their 
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recommendation(s). There should be critical ap- 
praisal of various in vitro equivalence measurements, 
in particular the use of multistage impingers and 
laser-based instrumentation. Manufacturers of non- 
approved nebulizers should be required to demon- 
strate equivalence of their own apparatus with the 
approved machine(s) if they wish to promote their use 
with specific nebulizer solutions. 
Adoption of the recommendations outlined 
above should set the standards whereby therapeutic 
equivalence of inhaled medications can be effectively 
determined. However, it should be noted that in 
the case of children, particularly young children, it 
may be unethical to utilize many of the recommen- 
dations given above, in particular radiolabelled 
aerosol deposition studies. 
Introduction 
Expiry of patent for a number of innovator inhaled 
medications for lung disorders, e.g. salbutamol, 
beclomethasone and cromoglycate, coupled with the 
requirement to replace chlorofluorocarbon (CFC) 
propellants with suitable alternatives (1,2), has her- 
alded the development of alternative products for 
inhalation therapy. These new products include gen- 
eric medications, novel compounds and new delivery 
devices. Accordingly, there is an increasing need to 
determine the equivalence of inhaled medications 
for marketing authorization. Equivalence is usually 
determined by clinical studies demonstrating compar- 
able bioavailability of generic compounds with estab- 
lished marketed medications. An exception has been 
made in many countries for inhaled medications be- 
cause of a lack of standardized or generally-accepted 
methods of demonstrating equivalence. The surro- 
gate criterion usually employed is in vitro equivalence 
without necessarily invoking comparable clinical effi- 
cacy. This departure from standard practice has been 
the subject of debate in Canada (3) and the U.S.A. 
(4). The end-point for any determination of equiva- 
lence of inhaled medications should be therapeutic 
equivalence. However, pharmaceutical equivalence is 
also an important parameter, provided appropriate 
tests and sampling equipment are employed. 
The British Association for Lung Research 
(BALR) has an interest in all aspects of research into 
the normal and abnormal functioning of the lungs, 
and considered it timely to assess current method- 
ology for determining equivalence of inhaled medi- 
cations. To that end, the BALR initiated a workshop 
whereby a group of clinical and non-clinical research- 
ers with expertise in different aspects of drug delivery, 
as well as representatives of relevant interested 
groups, discussed appropriate techniques for the 
determination of therapeutic equivalence. The present 
article reports the proceedings of the workshop and 
makes specific recommendations (see above) for the 
methodologies which should be adopted to determine 
the equivalence of metered-dose inhalers (MDIs) and 
dry-powder inhalers (DPIs), as well as for the use of 
spacer devices and nebulizers, for the management 
of asthma and other obstructive airway diseases. 
In principle, the recommendations could apply to 
inhalation products for other therapeutic indications. 
Three recent articles (5-7) provide additional 
discussion for the interested reader. 
Available Methodologies 
Four principal methodologies are currently avail- 
able to compare the equivalence of different inhaler 
devices (8). The first of these methodologies is an 
in vitro procedure usually based upon the inertial 
behaviour of particle clouds emitted by inhalers. 
Drug droplets or particles entering the apparatus, 
known as an impinger, are separated according to 
their size. In the simplest devices, the cloud is divided 
into two fractions, one larger and one smaller than a 
predetermined size. In multistage impingers, a num- 
ber of fractions are collected so that particle size 
distribution can be determined. One evaluation often 
made from the particle size distribution is the per- 
centage of drug contained in particles less than 
-5,um in diameter, often termed the ‘respirable 
fraction’. The respirable fraction is a measure of 
equivalence favoured by regulatory authorities but 
which may not correlate with efficacy in patients. 
Three in vivo methods are available to assess 
equivalence, namely (i) radioaerosol drug deposition 
studies (gamma scintigraphy) which assess the 
pattern of delivery to the patient and quantity distri- 
bution within the body; (ii) comparative pharmaco- 
dynamic and clinical efficacy studies and (iii) 
pharmacokinetic studies. Pharmacokinetic studies 
are of limited value in the study of inhaled medi- 
cations since the doses administered are small and the 
resulting serum concentrations either undetectable 
or so low as to be difficult to assay accurately or 
reproducibly. Furthermore, serum concentrations 
may not correlate with those of drug delivered to the 
lung, nor with its efficacy since, in addition to adsorp- 
tion via the respiratory tract, a considerable but 
variable amount of drug is deposited in the oro- 
pharynx and is swallowed and absorbed from the 
gastrointestinal tract (6). Recently, a new assay has 
been described whereby the amount of salbutamol 
excreted in the urine within 30 min of inhalation is 
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considered to be directly related to the amount 
deposited in the lungs (9). Although experimental 
and awaiting validation (lo), this assay could form 
the basis of a novel clinical equivalence test. 
In vitro Equivalence Studies 
A range of devices have been developed for 
determining the size of particles delivered by a thera- 
peutic aerosol and includes twin impingers, multi- 
stage liquid impingers, cascade impactors (e.g. the 
Andersen sampler), and forward light scattering 
laser-based sizing devices (11). The British Pharma- 
copoeia (BP) recommended method for determining 
the size distribution pattern of the emitted dose is to 
use a twin impinger (12). This glass or metal appar- 
atus is designed to be a model of the respiratory tract, 
with larger particles impacting in the upper chamber 
(which represents the oropharynx), and smaller 
particles (the ‘respirable fraction’) impacting in the 
lower chamber (representing bronchopuhnonary 
deposition). The respirable fraction measured in vitro 
invariably over-estimates the percentage of the 
emitted drug dose which is actually deposited in the 
lungs in vivo. This over-estimate is due, in part, to 
difEculty in delivering aerosols into the lungs and to 
the evolution of lung defence mechanisms designed 
to protect the lungs from inhaled foreign particles (8). 
Consequently, correlation between impinger esti- 
mates of drug distribution and clinical efficacy is 
greater in some studies (13,14) than in others (15). 
One problem with the BP recommendation for use of 
the twin impinger, is the requirement for 10 actu- 
ations of the MD1 into the apparatus before drug 
deposition in the chambers is determined. Although 
10 actuations allow mean percentage distributions of 
drug from different MDIs to be compared, it gives no 
information on the variability between actuations 
of the same inhaler. For example, an MD1 which 
delivers only 50% of the nominal metered dose on 
five actuations and 150% of the dose on the other 
five actuations would appear, using this test, to be 
equivalent to a device which delivered 100% of the 
nominal dose on each of the 10 actuations. In addi- 
tion, because the recommended dose from an MD1 is 
usually delivered in l-2 actuations, using a test with 
10 actuations would not appear to be appropriate for 
comparison of dose consistency. However, it should 
be noted that the BP test is not specifically‘designed 
to measure drug delivery in individual actuations, 
and there are other ways to measure this (16). 
A study using the twin impinger has claimed no 
differences between 12 different branded or generic 
salbutamol MDIs (17), although apparently statisti- 
tally significant differences between the MDIs were 
present both in the dose delivered and in deposition of 
drug. Small variability could be clinically significant 
because, although the dose-response curve to higher 
doses of salbutamol is comparatively flat, variation in 
delivery to the lungs might affect the magnitude of 
bronchodilation at lower doses. Significant differ- 
ences in the particle distribution of two generic beclo- 
methasone dipropionate (corticosteroid) MDIs and a 
branded MD1 have been found (18). If marked varia- 
tions in oropharyngeal deposition were demonstrated 
for corticosteroid MDIs, then this might significantly 
influence the incidence of local side-effects (candidi- 
asis and dysphonia) and systemic side effects. Hence, 
variation in in vitro measurements of equivalence 
raise issues not only of comparative clinical efficacy of 
different inhalers, but also of comparative safety. 
Although recommended as a standard, simple 
impingers have a number of shortcomings, including 
division of particles into only two size categories 
which are not precisely delineated. They also poorly 
mimic human lung geometry. Consequently, multi- 
stage impactors, e.g. the eight-stage Andersen 
impactor, should be the preferred test devices. A 
further advantage of this type of device is that an 
accurate assessment of mass median aerodynamic 
diameter (MMAD) and geometric standard deviation 
(GSD) of the aerosol can be determined. Recently, it 
has been shown that lung deposition efficiency is a 
sensitive function of MMAD and GSD (19). 
Radioaerosol Deposition (Gamma Scintigraphy) 
The basis of this technique is radiolabelling of the 
test formulation, usually with a gamma-emitting iso- 
tope, and after inhalation of the drug, scanning the 
upper body of the patient using a gamma camera to 
determine the distribution of the drug in different 
regions of the oropharynx, lungs and gastrointestinal 
tract (8). Thus, the technique enables bioequivalence 
between inhaled products to be determined since 
bioavailability, defined as the extent to which active 
drug becomes available at the site of action (in this 
instance, in the lung), can be assessed providing the 
deposition of radiolabel mimics that of the drug. One 
disadvantage of the technique is that it is seldom 
possible to radiolabel the drug molecule directly. 
Some radioaerosol methods use inert carrier particles 
(e.g. Teflon or polystyrene) which are labelled with 
99”Technetium (99m Tc) and are either substituted for 
the test drug or are mixed with the drug prior to 
delivery from the inhalation device (20). The success 
of such a method would,‘ therefore, depend upon 
the radiolabelled carrier and the drug itself having 
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similar physical properties and comparable distribu- 
tion patterns in the body. Aerosol distribution, as 
assessed by cascade impaction, of 99mTc relative to 
drug is dependent on the surfactant and drug combi- 
nation within the MDI (21). Validation of the tech- 
nique should be undertaken using a multistage 
impinger or impactor prior to any in vivo study, to 
ensure statistically equivalent distribution of drug 
and radioaerosol, and statistically equivalent distri- 
bution of drug for unlabelled and labelled formula- 
tions. More recently, techniques for direct labelling 
of the formulation with 99mTc have been developed so 
that the size distribution of the drug is unchanged by 
the radiolabelling procedure, and so that the radio- 
label acts as a marker for all sizes of drug particle (22). 
Using direct labelling, peripheral lung deposition of 
99mTc-labelled salbutamol has been found to be 
greater in normal subjects than in patients (23). These 
observations demonstrate that, when using gamma- 
scintigraphy for comparisons between different inha- 
lation devices, there needs to be standardization both 
of radiolabelling of drug and in the type of subject 
investigated. In addition, standard two-dimensional 
gamma scintigraphy cannot easily discriminate 
between aerosol deposition in the large airways and 
lung parenchyma, because the two zones overlap. 
Three-dimensional scintigraphy is more sensitive for 
discriminating between aerosol deposition in large 
and small airways (24). It should be noted, however, 
that for most drugs it is not well-established whether 
a drug should be targeted to the central or peripheral 
airways. Thus, although 3-D scintigraphy gives more 
detailed information on deposition site, the larger 
doses of radioactivity used invoke ethical consider- 
ations, particularly if intended for use in children. 
The predictive ability of radioaerosol deposition 
for clinical efficacy and safety of inhaled drugs has 
been little studied. A recent clinical study comparing 
two different salbutamol MDIs demonstrated that 
one device gave higher systemic absorption of drug 
and a significantly greater incidence of side effects, 
including tremor, tachycardia, hypokalaemia and 
electrocardiographic changes, than the other (25). In 
contrast, radioaerosol data showed the same device 
to have identical pulmonary deposition to the other 
device with lower oropharyngeal deposition (26). The 
latter observation would, therefore, not have pre- 
dicted the higher systemic absorption or incidence of 
side effects. The reason for the discrepancy between 
the studies is unknown. 
Clinical Efficacy Studies 
Clinical assessments are ultimately the most reli- 
able measure of the effectiveness of any medication, 
although they may not be easy to apply to an inhaled 
drug. For example, although beneficial effects on 
lung function measurements characteristically 
become rapidly apparent after administration of a 
single dose of bronchodilator drug, comparisons 
between different delivery devices may be obscured 
by a shallow dose-response curve. Comparison, 
therefore, between a range of doses, including low 
doses, would be more helpful in determining efficacy. 
Comparison of medications whose onset of clinically 
beneficial action is slower, e.g. inhaled corticosteroids 
and sodium cromoglycate, requires long-term evalu- 
ation. The U.S. Food and Drug Administration 
(FDA) is currently discussing recommendations for 
equivalence testing of bronchodilators to include not 
only single and cumulative dose-response broncho- 
dilation studies, but also bronchoprovocation studies 
(a standard methacholine challenge) and safety evalu- 
ations including serum potassium and heart rate (4). 
Several clinical comparison studies of different 
salbutamol MDIs have been published. In five studies 
comparing two different salbutamol MDIs, four 
studies showed significant differences in ability to 
produce bronchodilation (27-30) whereas the fifth 
study found no difference in degree of broncho- 
dilation or side effects between the two devices (15). 
A cautionary note should be struck in studies con- 
cluding no difference between devices or, indeed, 
in studies showing differences. In one study (31), 
although a greater bronchodilator response was 
demonstrated with a branded salbutamol device, 
compared with two different formulations of a com- 
petitor salbutamol inhaler, there was found to be no 
statistical difference between the products. However, 
the power of the study to detect a real difference was 
low and subsequent correspondence (32) suggested 
that it was highly unlikely that the small but consis- 
tent differences between the devices had arisen by 
chance. Thus, attention should be paid to statistical 
analysis in clinical comparison studies. Similarly, no 
differences in bronchodilator response between two 
salbutamol MDIs were found when comparisons of 
bronchodilator effects were made after the devices 
had been actuated (‘primed’) before use by the 
patient (30). Again it should be noted that, because of 
the small number of patients studied, there was only 
35% power to detect a 20% difference in FEV, . Even 
in studies where large numbers of subjects are 
recruited, high withdrawal rates can reduce the power 
of analysis and prevent definitive conclusions (33). 
An interesting development in assessing the effi- 
cacy of inhaled bronchodilator drugs is the use of 
normal subjects (34,35). Determination of the 
potency and efficacy of inhaled bronchodilator drugs 
258 D. F. Rogers and D. Ganderton 
in normal subjects is hindered because inherent bron- 
chomotor tone is low, and leads to marked variability 
when attempting to determine dose-response rela- 
tionships. However, normal subjects can be held in 
a steady state of partial bronchoconstriction by 
inhalation of an individual dosage regime of spas- 
mogen (methacholine or histamine), which increases 
the range of bronchodilation available and increases 
the precision of measurement of the dose-response 
relationship. Using this technique, it might be poss- 
ible to determine differences in efficacy of a range of 
inhaled medications. 
MDIlSpacer Device Combinations 
Guidelines on the management of asthma recom- 
mended that MDIs should be used with large-volume 
spacer devices to administer high-dose inhaled corti- 
costeroids to adults, and for the administration of 
asthma medications to young children (36). However, 
compatibility (involving more than just mouthpiece 
compatibility) between different MDIs and different 
large-volume spacers is a subject of debate (37,38). 
Several manufacturers of branded MDIs have devel- 
oped and tested spacer devices for use with their 
products. Some manufacturers of generic MDIs sug- 
gest that their products can be used with branded 
spacer devices. One spacer has been suggested as 
being compatible with any MDI. There appear to be 
no clinical data to support these suggestions. There 
will undoubtedly be compatibility between certain 
combinations of branded or generic MD1 with 
branded or generic spacer (39), but each combination 
requires examination. It should be noted, however, 
that the clinical relevance of differences in efficiency 
of pulmonary deposition of different bronchodilator, 
but not steroid, MDI/spacer combinations have been 
questioned (40). 
It is presently unclear how spray kinetics and, 
hence, adequate drug delivery are affected by different 
combinations of spacer and MD1 (8). Differences in 
propellant vapour pressure, drug concentration, sur- 
factant concentration and valve aperture can mark- 
edly affect plume geometry and drug deposition. 
Differences in static charge on the interior of the 
spacer can modify the passage of drug through the 
device (41). Use of an anti-static lining or washing of 
the spacer reduces the static charge. Consequently, it is 
not surprising that the particle size distribution from a 
beclomethasone MD1 differed markedly when deliv- 
ered through two different large-volume spacer devices 
(42), that delivery of terbutaline through two different 
spacers can differ nearly threefold (43) and that there 
is greater urinary excretion of salbutamol with one 
MDIlspacer combination than with another (44). 
Similarly, differences in the delivered dose of sodium 
cromoglycate have been found between three pro- 
prietary spacers and a home-made spacer device (45). 
From the above discussion, it may be concluded 
that different spacer devices can affect delivery of the 
same drug. The converse is also true - different drugs 
can behave differently when delivered through the 
same spacer. Fisons Pharmaceuticals have shown 
that, whereas the in vitro delivered dose from a 
branded salbutamol inhaler was similar whether 
tested alone or combined with a spacer, the delivered 
dose from a branded beclomethasone MD1 was 
doubled by use of the same spacer device (Fisons plc, 
data on file 1993). The same is also true for different 
formulations of the same drug. For example, the in 
vitro respirable fraction of a generic beclomethasone 
dipropionate inhaler was significantly reduced by use 
of a branded spacer device (Volumatic), whereas the 
respirable fraction delivered by the branded MD1 
was unchanged (46; Allen & Hanbury’s, data on file). 
These in vitro studies indicate that generic and 
branded drug formulations not only emit doses dif- 
ferently, but also behave differently depending upon 
the spacer device used. Thus, it must be considered 
advisable at present to use branded drug with recom- 
mended branded spacer. Nevertheless, the signifi- 
cance of these in vitro data is presently unclear, and 
clinical studies on the performance of generic 
beclomethasone MDIs with and without spacer 
devices are clearly warranted. 
Of importance is the observation that although a 
single actuation of salbutamol into a Volumatic 
spacer increases the amount of drug available for 
inhalation, multiple actuations of drug into the 
spacer prior to inhalation do not linearly increase the 
amount of drug available (41,47). In fact, the propor- 
tion of the total amount of drug is reduced. The 
reasons for the discrepancy between single and mul- 
tiple actuations is unclear but will relate to increasing 
droplet size due to sequential aggregation of par- 
ticles, displacement of aerosol out of the spacer or 
onto the spacer walls, or to electrostatic attraction of 
particles to the spacer and each other. These data 
emphasize the point that because different drug for- 
mulations and spacer devices have different physical 
and electrostatic properties, findings of one study of 
equivalence may not be applicable to other drug and 
device combinations. 
Safety Hazards from the ‘Inert’ Constituents of 
MDIs 
MDIs contain constituents other than the medi- 
cation, including propellants and surfactants, which 
may be associated with adverse reactions (48). For 
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example, in a recent study using a salmeterol MDI, 
fewer (1.1%) patients developed anomalous broncho- 
spasm compared with patients using placebo inhalers 
containing the surfactants oleic acid (1.8%) or leci- 
thin (1.7%) (48). Of concern is a case report of a 
patient with soya bean allergy who developed acute 
severe asthma when his medication was changed to 
an MD1 containing soya bean lecithin as a surfactant 
(49). Although generic products should utilize non- 
medication ingredients of the same nature and qual- 
ity as the branded product, possible differences in 
formulation indicate that formal comparative safety 
studies are appropriate. 
Current Licencing Requirements 
In the U.K., the Medicines Control Agency 
(MCA) has produced a guidance document on the 
replacement of CFCs in MDIs with the requirement 
that new products are ‘at least therapeutically 
equivalent’ with the innovative products. New pro- 
pellants are termed excipients. The major clinical 
requirements to be fulfilled are the efficacy and safety 
of the reformulated innovator product or the generic, 
with excipient. The guidelines state that demonstra- 
tion of pharmaceutical equivalence is insufficient and 
that demonstration of at least therapeutic equiva- 
lence is required. Although not specifically stated, 
there is an implication that a range of equivalence 
methods be used for any product with novel excipi- 
ents, including in vitro and/or in vivo deposition 
studies, pharmacokinetic studies and pharmaco- 
dynamic/clinical efficacy studies. Interestingly, for the 
assessment of therapeutic equivalence of inhaled 
bronchodilators, only single-dose short-term studies 
are indicated. The criteria for testing of glucocorti- 
costeroid excipients are more exacting. For the anti- 
allergic excipients, equivalence testing in indirect 
challenge studies (exercise, cold air or sodium meta- 
bisulphite) is recommended. Safety testing is outlined 
in considerable detail with specific recommendations 
made, and with the statement that although animal 
toxicology will have been assessed, this does not 
remove the need for clinical safety studies in man. 
In the U.S.A., the Food and Drug Administration 
(FDA) has produced interim guidelines on the best 
protocols for determining equivalence of generic 
salbutamol (albuterol in the U.S.A.) MDIs. The 
guidelines recommend one safety study, involving 
single-day recording of adverse reactions to increas- 
ing doses of drug, and one pharmacodynamic study, 
involving a separate-day bronchoprovocation or 
bronchoprotection test to single MD1 doses, to dem- 
onstrate bioequivalence with the innovator products 
(Ventolin and Proventil in the U.S.A.). However, 
because of the limited experience’ of the FDA with 
equivalence protocols, manufacturers are ‘encour- 
aged to explore these and other methods to assess 
their general applicability’, and attention is drawn to 
the fact that the recommended methodologies are 
‘not rigid’. Nevertheless, the FDA is sponsoring 
development of pharmacodynamic methodology for 
determining albuterol MD1 equivalence (51,52). 
Discussion 
A number of issues need to be considered when 
undertaking studies of equivalence of inhaled medi- 
cations. One obvious, but often overlooked, problem 
is that the majority of patients are non-controlled 
and are an important source of variability. Use of 
‘controlled’ subjects who have experience of clinical 
assessments, including inhaler technique, overcomes 
this problem but is not representative of the majority 
of patients who will ultimately use the medication 
(53,54). It may be reasonable to use a selection of 
both experienced and non-experienced subjects in 
equivalence studies. It should also be noted that 
there are no clear recommendations on how much 
inhalation effort should be employed for different 
devices-manufacturer’s recommendations for DPIs 
are for deep inhalation, compared with the chest 
physician who may suggest inhaling as hard as the 
patient is able. Instructions clearly need to be 
reviewed in the light of recent experimental evidence 
for an optimal inhaler technique (55), i.e. gentle 
exhalation to residual volume followed by slow inha- 
lation with a 10 s breath-hold. The development of a 
novel microprocessor-controlled MDI, SmartMist 
(Aradigm Corporation, Hayward, CA) may mini- 
mize variability in patient inhalation technique and 
aid standardization (56). The device is hand-held and 
breath-actuated to deliver a drug bolus at a pre- 
programmed point in the inhalation cycle, defined by 
both flow rate and cumulative inspiratory volume 
parameters. For currently marketed DPIs, efficacy is 
directly related to inspiratory flow rate (57,58) which 
varies between patients. The resistance to airflow 
of DPIs also varies significantly, and it is suggested 
that the performance of DPIs should be assessed at 
comparable pressure drops across the device (e.g. 100 
and 200 mmH,O) to produce clinically relevant 
inspiratory flow rates for different devices (59). In 
regard to assessments of equivalence of drugs admin- 
istered through spacers, the timing of inhalation 
needs to be standardized because the maximum dose 
is received when inhalation is immediately after 
actuation of the MD1 into the spacer (41). Another 
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consideration in equivalence is whether or not to 
‘prime’ the MD1 before testing, because the dose 
delivered by an initial actuation can be markedly less 
than that in subsequent actuations (16). The amount 
of drug in an initial actuation following a period of 
non-usage is dependent upon the rest position of the 
MDI, with the greatest departures from the nominal 
dose being when stored valve-down. Thus, it would 
seem reasonable to standardize for primed MDIs. 
However, this is in contrast to patient usage and it 
may, therefore, be better to obtain data for both 
primed and unprimed devices. 
Differences in regional deposition within the lung 
may significantly affect drug availability, duration at 
site of action and removal from site of action. 
Factors which promote regional differences in lung 
absorption include barrier thickness (mucus layer, 
mucosal and submucosal thickness), blood flow, 
surface area, concentration gradient of the solute, 
mucociliary clearance and drug metabolism. Differ- 
ent mechanisms will affect drug absorption at differ- 
ent sites in the lung. For example, there is higher 
permeability to hydrophilic compounds in peripheral 
regions of the lung, whereas mucociliary clearance 
will only affect drugs deposited more centrally. In the 
rabbit, modelling the effects of regional deposition of 
peptide-proteins on their absorption profile demon- 
strates that parallel elimination pathways (e.g. muco- 
ciliary clearance) significantly intluence both the 
extent and apparent rate of drug absorption (60). It 
should be considered whether or not site of drug 
action should be specified in equivalence studies. 
Finally, although studies of clinical efficacy and 
in vitro deposition are the principal recommended 
assessments of this workshop for determining equiva- 
lence of inhaled medications, all studies are comple- 
mentary and form feedback loops leading to 
pharmacodynamic assessment. 
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